Darden continues to outperform the consumer discretionary sector. Citi and Raymond James expect another solid quarter. GLP-1 drugs may shift menu preferences toward smaller plates and protein options.
Options imply a 4% move post-earnings. The K-shaped economy and consumer pullback risk are noted, but Darden's casual dining segment trends remain strong.